Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 5/20 | 0.48 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2899849 | 1.00 | KDM4E (0.50) | KDM4EALDH1A1GRM1MAPTRECQL | |
| SCHEMBL3329389 | 1.00 | KDM4E (0.50) | KDM4EALDH1A1GRM1MAPTRECQL | |
| SCHEMBL2743003 | 0.80 | TRPV1 (0.46) | HSD11B1PRKCQPRKCD | |
| SCHEMBL4425614 | 0.80 | TRPV1 (0.46) | HSD11B1PRKCQPRKCD | |
| SCHEMBL232897 | 0.80 | DRD2 (0.58) | KDM4EALDH1A1MAPTRECQLDRD2 | |
| SCHEMBL30101378 | 0.80 | DRD2 (0.58) | KDM4EALDH1A1MAPTRECQLDRD2 | |
| SCHEMBL2425193 | 0.79 | PRKCQ (0.45) | PRKCQPRKCD | |
| SCHEMBL2897789 | 0.79 | MAPT (0.42) | MAPTGRM5PRKCQPRKCD | |
| SCHEMBL2895112 | 0.79 | MAPT (0.42) | MAPTGRM5PRKCQPRKCD | |
| SCHEMBL2421374 | 0.79 | PRKCQ (0.45) | PRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716125-B1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | ASTRAZENECA AB (SE) | 2013-06-19 | — | — | EP | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-7691892-B2 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| CN-101679261-A | Piperazine and piperidine mglur5 potentiators | ASTRAZENECA AB | 2010-03-24 | — | — | CN | disclosed |
| EP-2134687-A1 | PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS | AstraZeneca AB (SE) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008112440-A1 | PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112440-A1 | PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | WO | disclosed |
| US-20070197549-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
| EP-1716125-A1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060004021-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| WO-2005080356-A1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | GRM5, GRM1, GRM2 | KDM4E 3322/4885ALDH1A1 1506/4885GRM1 2/4885 |
| US-20060004021-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM4 | KDM4E 2623/4885ALDH1A1 2803/4885GRM1 1/4885 |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | GRM5, GRM1, GRM3 | KDM4E 1679/4885ALDH1A1 1232/4885GRM1 2/4885 |
| US-20070197549-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM4 | KDM4E 2698/4885ALDH1A1 2915/4885GRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.